NCT00170430 is a Phase 3 clinical trial of Fluconazole in Bacterial Diseases, sponsored by University of Washington.

Who is sponsoring NCT00170430?

NCT00170430 is sponsored by University of Washington.

What drugs are being tested in NCT00170430?

Interventions in NCT00170430: Fluconazole, Metronizadole.

What condition does NCT00170430 study?

NCT00170430 studies Bacterial Diseases, Other Mycoses, Sexually Transmitted Infection.

Is NCT00170430 still recruiting?

NCT00170430 is currently completed. Last updated 16 March 2010.

Last reviewed 2010-03-16 · How we verify

NCT00170430

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reducing Vaginal Infections in Women at Risk for HIV-1

Completed Phase 3 Last updated 16 March 2010

What this trial tests

Phase 3 trial testing Fluconazole in Bacterial Diseases in 400 participants. Completed in 1 December 2006.

Timeline

1 May 2003

Primary endpoint
1 December 2006

1 December 2006

Quick facts

Lead sponsor	University of Washington
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	400
Start date	1 May 2003
Primary completion	1 December 2006
Estimated completion	1 December 2006
Sites	1 location across Kenya

Drugs / interventions tested

Fluconazole (fluconazole) — full drug profile →
Metronizadole — full drug profile →

Conditions studied

Bacterial Diseases — all drugs for Bacterial Diseases →
Other Mycoses — all drugs for Other Mycoses →
Sexually Transmitted Infection — all drugs for Sexually Transmitted Infection →

Sponsor

University of Washington

Who can join

16 and older, female only, with Bacterial Diseases or Other Mycoses. Healthy volunteers can join.

Sponsor's own description

The purpose of this study is to see if taking medication once a month can help to decrease the risk of vaginal infections. Additionally, researchers will study whether personal habits, such as douching, bathing, and sexual practices can influence the risk of vaginal infections. Vaginal infections may influence the risk of becoming infected with HIV-1 and other sexually transmitted diseases (STDs). Study participants will include 400 female prostitutes ages 16 and older, living in Mombasa. Study procedures will include sexual behavior questions, physical examinations including pelvic exams, testing of vaginal and cervical secretions for STDs, urine collection and blood samples. Participants will receive 2 different types of pills to treat vaginal infections (metronidazole or fluconazole) or placebo (contains no medication). Participants will be involved in study related procedures for 1 year and will return to the study clinic at one month intervals.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.
McClelland RS, Richardson BA, Hassan WM, Chohan V, et al · · 2008 · cited 68× · PMID 18444793 · DOI 10.1086/587490

Verify or expand the search:

Other trials of Fluconazole

Trials testing the same drug.

NCT07395024 — A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults · Phase 1 · recruiting
NCT06922344 — Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor · Phase 4 · recruiting
NCT05421858 — A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invas · Phase 3 · recruiting
NCT06345794 — A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants · Phase 1 · completed
NCT06822166 — Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride · Phase 1 · completed

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00170430 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 16 March 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00170430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing